Tectonic Therapeutic Secures $236.9M Runway and Advances TX45, TX2100 Trials
Tectonic Therapeutic held $236.9 million in cash as of March 31, 2026, securing operational runway into Q4 2028 and supporting ongoing trials. The company advanced its TX45 APEX Phase 2 enrollment nearing completion, initiated TX45 ALPINE Phase 2 in PH-ILD, and dosed four cohorts in TX2100 Phase 1a.
1. Q1 2026 Financial Position
As of March 31, 2026, Tectonic Therapeutic held $236.9 million in cash and cash equivalents, providing a runway into the fourth quarter of 2028 and underpinning its strategic clinical development programs.
2. Pipeline Advancements
In February 2026, the company initiated the TX45 ALPINE Phase 2 trial in pulmonary hypertension associated with interstitial lung disease and activated its first site, while enrollment in the TX45 APEX Phase 2 trial for PH-HFpEF is nearing completion. Additionally, four cohorts have been dosed in the TX2100 Phase 1a healthy volunteer study, with topline data expected by the end of Q3 2026.
3. Board and Governance Updates
In February, François Nader, M.D., was appointed Chair of the Board, and in April, Jessica Chutter joined as an independent director, bolstering strategic oversight and industry expertise as the company advances its pipeline.